APR 24 2027
Organogenesis Holdings — ReNu (cryopreserved amniotic suspension allograft) $ORGO
for management of pain in symptomatic knee osteoarthritis
Accepted JUL 6 2026.
About
Knee osteoarthritis is a degenerative joint disease that causes progressive cartilage loss, bone changes, and inflammation, making it a leading cause of disability in adults. ReNu is a cryopreserved amniotic suspension allograft injected directly into the knee joint. This therapy may help manage pain by delivering a mix of biological components to the arthritic environment, potentially offering an alternative to purely symptomatic treatments.
Pivotal trial
This study is being conducted to evaluate the efficacy and safety of ASA compared to placebo in the management of osteoarthritis (OA) symptoms of the knee.
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on ReNu
- Does BioMarin (BMRN) Expanding Into ReNU Syndrome Refine Its Rare Disease Pipeline Strategy? - simplywall.st
- RENUEN CORP Revenue Breakdown – OTC:RENU - TradingView
- BioMarin and n-Lorem Foundation Enter Research Collaboration for ReNU Syndrome Treatment - Pharmaceutical Executive
- BioMarin and n-Lorem partner on early research for ReNU syndrome therapy - Pharmaceutical Technology
- Renu Vig’s tenure ends, Meenakshi Goyal to be acting V-C of Chandigarhs Panjab University - The Tribune
Sponsor Watch — recent news on Organogenesis Holdings
- Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis
- Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results
- Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®
- Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain